Skip to main content
PLYX
NASDAQ Life Sciences

Polaryx Q3 10-Q: Going Concern Reaffirmed, $8.4M Cash Funds Operations Only Through Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.84
Mkt Cap
$93.71M
52W Low
$1.69
52W High
$48.91
52W Position info
8.9% above low
Off High info
96% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

PLYX is trading near its 52-week low of $1.69 (8.9% above the low) on light trading volume (0.2× avg).

Summary

Polaryx reported $8.4 million of cash as of September 30, 2026 — enough to fund operations only through Q1 2027 — and reiterated going-concern doubt while quarterly R&D spending jumped to $2.5 million on SOTERIA trial costs.


Key Events · Earnings and Guidance · PLYX

  • Going Concern Doubt Reaffirmed

    The 10-Q states conditions 'raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.'

  • Cash Runway Ends Q1 2027

    Cash and cash equivalents were $8.4 million at September 30, 2026; management estimates this funds operating expenses and capital expenditures only through the first quarter of 2027.

  • Cash Burn Accelerates on Trial Costs

    Operating cash use was $6.5 million for the nine months ended September 30, 2026 versus $2.5 million a year earlier; Q3 R&D rose to $2.5 million from $514 thousand, including $2.0 million of SOTERIA CRO expense.

  • May 2026 Raise Largely Consumed

    The company issued 2,502,696 shares at an average $4.00 per share for $10.0 million gross ($169 thousand offering costs) in May 2026 — the main source of the current cash balance.


Analysis · PLYX · Life Sciences

With $8.4 million in cash at September 30, Polaryx says it can fund operations only through the first quarter of 2027 — roughly one quarter of runway — and formally repeats that conditions raise substantial doubt about its ability to continue as a going concern. The burn is accelerating as the SOTERIA trial ramps: operating cash use was $6.5 million in the first nine months versus $2.5 million a year earlier, and third-quarter R&D jumped to $2.5 million from $514 thousand on $2.0 million of CRO costs. Another raise is therefore effectively required within months, and the May 2026 equity sale (2.5 million shares at $4.00 for $10.0 million) is already largely spent. The offsetting positive is that trial spending is going into the clinic rather than overhead, but shareholders face near-certain further dilution at whatever price the market offers.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PLYX was trading at $1.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.7M. The 52-week trading range was $1.69 to $48.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PLYX - Latest Insights

PLYX
Aug 13, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.45
Real-time Price: $1.83 info
Change: -$0.620 (-25%) info
Market Cap: $88.227M info
PLYX
May 28, 2026, 8:00 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $2.95
Real-time Price: $1.83 info
Change: -$1.12 (-38%) info
Market Cap: $88.227M info
PLYX
May 28, 2026, 4:31 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.05
Real-time Price: $1.83 info
Change: -$1.22 (-40%) info
Market Cap: $88.227M info
PLYX
May 28, 2026, 8:37 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $2.51
Real-time Price: $1.83 info
Change: -$0.680 (-27%) info
Market Cap: $88.227M info
PLYX
May 14, 2026, 8:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.61
Real-time Price: $1.83 info
Change: -$1.78 (-49%) info
Market Cap: $88.227M info